S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
Log in

Molecular Templates (NASDAQ:MTEM) Rating Increased to Buy at Zacks Investment Research

Last updated on Tuesday, February 23, 2021 | 2021 MarketBeat

Molecular Templates (NASDAQ:MTEM) was upgraded by Zacks Investment Research from a "hold" rating to a "buy" rating in a research report issued to clients and investors on Tuesday, Zacks.com reports. The brokerage presently has a $13.00 price target on the biotechnology company's stock. Zacks Investment Research's target price suggests a potential upside of 10.54% from the stock's current price.

According to Zacks, "Molecular Templates Inc. is focused on the discovery, development and commercialization of next-generation immunotoxins called Engineered Toxin Bodies for the treatment of cancers and other serious diseases. Molecular Templates Inc., formerly known as Threshold Pharmaceuticals Inc., is headquartered in Austin, United States. "

Separately, UBS Group started coverage on Molecular Templates in a report on Monday, February 1st. They issued a "neutral" rating and a $13.00 target price for the company. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The company has an average rating of "Buy" and an average target price of $18.33.

Shares of NASDAQ:MTEM opened at $11.76 on Tuesday. The stock has a fifty day simple moving average of $11.85 and a two-hundred day simple moving average of $10.78. The stock has a market capitalization of $587.58 million, a price-to-earnings ratio of -5.76 and a beta of 2.08. Molecular Templates has a 12-month low of $7.51 and a 12-month high of $19.12. The company has a current ratio of 3.21, a quick ratio of 3.21 and a debt-to-equity ratio of 0.18.

In other news, major shareholder Target N. V. Biotech acquired 80,000 shares of the business's stock in a transaction that occurred on Monday, February 1st. The stock was bought at an average price of $11.69 per share, with a total value of $935,200.00. Following the completion of the acquisition, the insider now directly owns 6,540,331 shares of the company's stock, valued at approximately $76,456,469.39. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Target N. V. Biotech acquired 1,185,770 shares of the business's stock in a transaction that occurred on Thursday, February 18th. The stock was purchased at an average cost of $12.65 per share, with a total value of $14,999,990.50. Following the acquisition, the insider now directly owns 7,726,101 shares of the company's stock, valued at $97,735,177.65. The disclosure for this purchase can be found here. In the last three months, insiders acquired 1,470,770 shares of company stock valued at $17,967,891. Corporate insiders own 38.20% of the company's stock.

Several institutional investors and hedge funds have recently modified their holdings of the stock. JPMorgan Chase & Co. grew its holdings in shares of Molecular Templates by 3.2% in the fourth quarter. JPMorgan Chase & Co. now owns 87,743 shares of the biotechnology company's stock worth $823,000 after acquiring an additional 2,690 shares during the period. IHT Wealth Management LLC grew its holdings in Molecular Templates by 4.3% during the fourth quarter. IHT Wealth Management LLC now owns 24,500 shares of the biotechnology company's stock valued at $230,000 after purchasing an additional 1,000 shares during the period. Jane Street Group LLC bought a new stake in Molecular Templates during the fourth quarter valued at about $95,000. Squarepoint Ops LLC grew its holdings in Molecular Templates by 93.7% during the fourth quarter. Squarepoint Ops LLC now owns 87,686 shares of the biotechnology company's stock valued at $823,000 after purchasing an additional 42,420 shares during the period. Finally, Endurant Capital Management LP grew its holdings in Molecular Templates by 61.1% during the fourth quarter. Endurant Capital Management LP now owns 681,243 shares of the biotechnology company's stock valued at $6,397,000 after purchasing an additional 258,456 shares during the period. 60.73% of the stock is owned by institutional investors.

Molecular Templates Company Profile

Molecular Templates, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. Its proprietary drug platform technology is engineered toxin bodies. The company's lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed and refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin's lymphoma.

Read More: Understanding each part of a balance sheet

Get a free copy of the Zacks research report on Molecular Templates (MTEM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Molecular Templates (NASDAQ:MTEM)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]


7 Outdoor Recreation Stocks For Growth And Dividends

If American’s liked outdoor activities before, they love them even more now. The COVID-19 pandemic has done many things, and one of them is reinvigorating American’s love of the outdoors. Data from across the industry shows a sustained uptick in revenue that has the entire complex moving higher.

The RV Industry Association, for example, reports shipments of RVs are up greater than 30% in 2020 and are expected to grow another 20% or more in 2021. If data from the two of the industry’s largest manufacturers are any indication, that forecast is very conservative.

And the gains aren’t limited to RVs. Everything that has anything to do with outdoor recreation is booming. Sales at Dicks Sporting Goods, an iconic brand for retail and the outdoors, has seen a sustained 20% increase in revenue since the 2nd quarter shutdowns. If anything, revenue in this sector is being held back by rapidly declining inventory and tight shipping conditions.

The stocks we are about to show all have something in common; the outdoors. Within the group, you will find everything from RVs to Radios and everything in between an outdoor enthusiast could need or want. Some pay dividends and some don’t, but all will deliver solid returns to investors in 2021.

View the "7 Outdoor Recreation Stocks For Growth And Dividends".

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.